In this episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the most important and clinically transformative studies being presented at the ESC 2022 Conference, August 26-29.
Day One includes: more data from the EMPEROR trial on the mechanisms and clinical benefits of SGLT2i in heart failure, the TAILOR-PCI randomized trial on genotype-guided oral P2Y12 inhibitor therapy, phase 2 data from the ENTRIGUE study on pegozafermin for the treatment of severe hypertriglyceridemia, and the results of the TIME trial on the timing of morning versus evening medication. Also on Day One, Dr. Valentine Fuster will present the results of the SECURE trial, a polypill strategy in secondary prevention. There will also be a presentation of the ASCEND study on the effects of aspirin and omega−3 fatty acid supplements on heart failure. Dr. Bhatt will present data from the REDUCE-IT trial on the significant reduction in ST-Elevation MI with icosapent ethyl. Day One will also cover the EXHAUSTION project, investigating air temperature and cardiovascular disease, as well as the ADDICT-ICCU study on carbon monoxide and acute cardiac events.
Day Two will include: a presentation by Davada Perera on REVIVED, investigating percutaneous revascularization for ischemic ventricular dysfunction, ALL-HEART data on allopurinol and cardiovascular outcomes in ischemic heart disease, and a major presentation by Scott Solomon on the DELIVER trial, examining dapagliflozin in heart failure with mildly reduced and preserved ejection fraction. There will also be a number of pooled analyses on Day Two, including one looking at DAPA-HF and DELIVER, and a pre-specified meta-analysis of DELIVER and EMPEROR-Preserved. Together these studies will firmly cement the concept of the SGLT-2 inhibitors class as a heart failure medication.
Day Three opens with an important presentation on INVICTUS, exploring rivaroxaban versus VKA for rheumatic atrial fibrillation. There will also be a group of presentations on some modest but significant Phase 2 trials on factor XIa inhibitor asundexian. Additionally, Renalto Lopes will present data on the APOLLO trial exploring apixaban for prophylaxis of thromboembolic outcomes in COVID-19, and the five-year data from the MOMENTUM 3 study on LVAD Therapy will be presented.
On the fourth and final day, presentations include the clinical outcomes at 5 years of follow-up in the ISCHEMIA-CKD EXTEND trial, the review of the MASTERDAPT trial data at 15 months, the primary results of FOURIER-OLE, and data from the PANTHER Trial on P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease.
ESC 2022 promises to be a rich and rewarding experience for those who can attend in person or participate virtually.